Spruce Biosciences

Update in progress

SPRB (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Spruce Biosciences, Inc. is a biopharmaceutical company developing therapies for neurological and related disorders. Its programs include TA-ERT for Sanfilippo Syndrome Type B; Tildacerfont for congenital adrenal hyperplasia (CAH), including a Japan collaboration with Kaken Pharmaceutical to develop and commercialize it; and SPR202 for CAH. The company also has licensing and collaboration agreements with Eli Lilly. Founded in 2014, it is based in South San Francisco, California.

Company score

Sentiment: 0.19; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.17; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.13; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive